Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > So, what do I think? Or say?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(192)
•••
Comment by craighenryon Feb 20, 2021 11:06am
118 Views
Post# 32618492

RE:RE:RE:RE:RE:So, what do I think? Or say?

RE:RE:RE:RE:RE:So, what do I think? Or say?
zwerp2000 wrote: And for the record, not that it needs to be said, I don't rely on JDs due diligence. Why would I? Has he ever been right over all these years? 


Of COURSE you do you pu$$y!! That is why you are begging JD to update his website. You dont have the ability to do DD on your own. That is why you RELY on people such as JD to SPOON FEED you. The clown you are probably bought BTI at the absolute highs because you read this forum and were all hyped because of the comments and opinions being posted on this board. You are tooooooo stupid to realize this forum is for OPINIONS!! You are too stupid to realize people are entitled to their OPINIONS and their OPINIONS could very well be wrong!!!! Now you are PISSED off because you are getting your assss kicked on your bioasis investment, so you blame JD!!! And to be honest I hope it burns your assss every day you look at the massive red stain on your trading acct!!! Typical coward. Won't take accountability.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities